| News
EvokAI to acquire Advancience
30.05.2022
EvokAI Creative Labs Inc. has agreed a deal to acquire Advancience. The diagnosis profiles enhanced by Artificial Intelligence (AI) developed by Advancience can be used to help monitor cognitive alterations with the aid of computer games. This should make it easier to diagnose neurodegenerative diseases such as Alzheimer’s at an early stage.

EvokAI Creative Labs is taking over Advancience AG as part of a deal announced by the AI-powered medtech firm. Both companies are based in Allschwil in the canton of Basel-Landschaft.
EvokAI is building a platform for brain health and recovery. “Our concept is aimed at measuring the invisible”, comments Alejandro Antalich, co-founder of EvokAI, in the press release. “It is also tremendously important to be able to spot arising problems as soon as possible; knowing what’s typical is the most important foundation to know if something is out of the ordinary”, he adds.
The acquisition of Advancience brings the company one step closer to bridging the gap between neuroscience and AI. As part of EvokAI’s expansion plan, the takeover of Advancience will enable it to combat Alzheimer’s.
Advancience participated in DayOne Accelerator
Advancience is working with the University of Basel. The company offers digital, fully automated tests, in which it integrates gaming elements. By simulating various scenarios, these can be regarded as a “perfect tool to probe, assess and even predict human behavior”, the press release states.
DayOne, the Basel-based startup accelerator for the life sciences sector, is a partner of both EvokAI and Advancience. DayOne and Basel Area Business & Innovation, the investment and innovation promotion agency, awarded Advancience one of the three startup spots for its DayOne Accelerator program at Technologiepark Basel in 2019, supporting it with a grant of 70,000 Swiss francs in the process.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Space Pharmaceuticals establishes presence in Basel
Space Pharmaceuticals AG is strengthening the life sciences cluster in the Basel Area. At its research lab, the cheminformatics company...
Read MoreNextImmune to benefit from Venture Kick financing
The startup accelerator Venture Kick is supporting NextImmune with financing in the amount of 150,000 Swiss francs. The spin-off from...
Read MoreOECD impressed by the canton of Jura’s innovation system
The OECD has examined the innovation systems in place in rural areas of its member states, including the canton of...
Read Moreti&m opens branch in Basel
ti&m now has an office in Basel. With this action, the company specializing in digitization, security and innovation projects is...
Read MoreWhat can artificial intelligence do for health?
Algorithms help diagnose and treat diseases, discover new drugs and personalize prevention. Thus, the potential of artificial intelligence has been...
Read MoreEconomic promotion agency creates 55 new jobs in Jura
The economic promotion agency of the canton of Jura supported a total of 26 companies in founding, establishing a presence...
Read More